MedTrace Logo

PDR001 + Panobinostat for Melanoma and NSCLC

NCT03982134 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-10-04

No results posted yet for this study

Summary

The purpose of this research study is to find the dose of the study drug PDR001 that, when given in combination with the drug Panobinostat, results in the best outcomes for metastatic melanoma and non-small cell lung cancer (NSCLC)

Conditions

Interventions

DRUG

PDR001

PDR001 is a humanized IgG4 antibody

DRUG

Panobinostat

Panobinostat is a Histone deacetylase inhibitor (HDACi).

Sponsors & Collaborators

Principal Investigators

  • Muhammad Furqan, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2021-05-01
Completion
2022-05-01
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03982134 on ClinicalTrials.gov